CHVB-032
CHVB-032 is an antiviral agent and SFV nsP1 inhibitor. CHVB-032 inhibits the methyltransferase and guanylyltransferase activities of nsP1, blocks viral RNA capping process, and suppresses post-entry steps in CHIKV replication. CHVB-032 inhibits CHIKV replication across different isolates, but shows no activity against other alphaviruses. CHVB-032 can be used in research related to chikungunya fever and CHIKV infection.
For research use only. We do not sell to patients.
- CAS No.: 1309199-66-3
- Formula: C18H22FN5O
- Molecular Weight:343.40
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
All DNA/RNA Synthesis Isoforms
More
Biological Activity
Description
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| Vero | CC50 |
165 μM
Compound: 31a
|
Cytotoxicity against African green monkey Vero cells assessed as reduction in overall metabolic activity incubated for 5 days by MTS reagent based absorbance method
Cytotoxicity against African green monkey Vero cells assessed as reduction in overall metabolic activity incubated for 5 days by MTS reagent based absorbance method
|
[PMID: 38104375] |
In Vitro
CHVB-032 potently and selectively inhibits the replication of CHIKV 899 in Vero cells, with an EC50 of 2.7 µM and a CC50 greater than 75 µM[1].
CHVB-032 inhibits viral RNA replication of various CHIKV isolates in Vero cells, with EC50 values ranging from 1.2 to 7.3 µM, but shows no activity against other tested alphaviruses[1].
CHVB-032 (50-1000 µM; 30 min) completely inhibits both MTase and GTase activities of purified wild-type SFV nsP1 at concentrations ranging from 50 to 1000 µM[1].
CHVB-032 potently inhibits the replication of CHIKV-899 in Vero cells, with an EC50 of 2.7 μM and a CC50 greater than 75 μM[2].
CHVB-032 (0.63-20.00 μM) reduces viral RNA levels of CHIKV-899 and production of infectious progeny viruses in Vero cells in a dose-dependent manner in vitro, with a reduction of over 4-log10 at the highest tested concentration[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:Vero cells
-
Concentration:20 µM
-
Incubation Time:added at 0, 2, 4, 6, 8, 10 h post-infection
-
Result:Reduced viral RNA and infectious virus loads when added up to 4 hours post-infection, indicating inhibition of a postentry step in the CHIKV replication cycle.
Chemical Information
-
CAS No. 1309199-66-3
-
Molecular Weight 343.40
-
Formula C18H22FN5O
-
SMILES
O=C(N1CCN(CC1)C2=NC(NCC)=NC(C)=C2)C3=CC=C(C=C3)F
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
Purity & Documentation
References
[2]. Abdelnabi R, et al. Novel Class of Chikungunya Virus Small Molecule Inhibitors That Targets the Viral Capping Machinery. Antimicrob Agents Chemother. 2020;64(7):e00649-20. Published 2020 Jun 23. [Content Brief]
[3]. Kovacikova K, et al. Small-Molecule Inhibitors of Chikungunya Virus: Mechanisms of Action and Antiviral Drug Resistance. Antimicrob Agents Chemother. 2020;64(12):e01788-20. Published 2020 Nov 17. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
CHVB-032 Related Classifications
HY-184263 Related Classifications
Powered by Bioz